Healthy Volunteers
Conditions
Brief summary
This study is the first administration of LG-0317 to humans. The purpose of the study is to evaluate safety/tolerability and pharmacokinetics in healthy subjects. The intention of this study is to provide confidence in the safety of the molecule to inform progression to further proof-of-concept studies.
Detailed description
This study consists of three parts: single ascending dose, food effect , and multiple ascending dose. The single ascending dose part consists of a screening period (4 weeks), a dosing observation period and a follow-up period. Participants in different dose groups will be enrolled sequentially according to the dose escalation principle. In the food effect part, eligible participants will be randomly assigned to Sequence 1 or Sequence 2 prior to dosing in the first period. Participants will receive a single oral dose of LG-0317 tablet either under fasting conditions or after a high-fat, high-calorie meal, depending on their assigned sequence. The multiple ascending dose part will include 3-4 dose groups, and the dose levels will be determined based on the safety, tolerability, and available PK and PD data obtained from the single ascending dose part.
Interventions
DRUGLG-0317
Subjects are planned to be dosed in oral tablet, with single and multiple ascending doses
DRUGPlacebo
Subjects are planned to be dosed in oral tablet, with single and multiple ascending doses
Sponsors
LinGang Laboratory
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Intervention model description
Study drug: LG-0317 and placebo. In the single ascending dose part, subjects will be randomized and dosed in different cohorts with a single dose. In the multiple ascending dose part, subjects will be randomized and dosed in different cohorts with multiple doses.
Eligibility
Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy male and female subjects age 18 to 45 years of age included. * Participant must weigh at least 50 kg to participate in the study and must have a body mass index (BMI) within the range of 18-32 kg/m2 inclusive. * The participant has normal results or abnormalities without clinical significance as judged by the investigator for vital signs, physical examination, laboratory tests (complete blood count, blood biochemistry, coagulation function, urinalysis), 12-lead electrocardiogram (ECG). * Fully understand the trial content, procedures, and possible adverse reactions; voluntarily participate and sign the informed consent form (ICF). * Able to communicate well with the study personnel, and understand and comply with the relevant requirements of the trial.
Exclusion criteria
* History of allergic diseases, or known allergy to the investigational product, its excipients, or related products. * History of significant cardiovascular, respiratory, renal, neurological disease. * History of psychiatric disorders, substance abuse, or drug dependence. * Suicidal risk according to the Columbia-Suicide Severity Rating Scale (C-SSRS) or based on the investigator's clinical judgment, or history of self-injurious behavior. * Smoking ≥5 cigarettes per day within 3 months prior to screening. * Use of any prescription drugs, over-the-counter drugs, herbal medicines, or health supplements within 14 days prior to the first dose. * Participation in another clinical trial and receipt of an investigational drug within 3 months prior to the first dose. * Blood donation or significant blood loss (\>400 mL) or blood transfusion within 3 months prior to the first dose. * Positive results for hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV-Ab), human immunodeficiency virus antibody (HIV-Ab), or Treponema pallidum antibody. * Women of child-bearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant. * Pregnant or lactating females or subjects (including males) planning to father a child during the trial or within 3 months after the last dose, unwillingness to use effective non-pharmacological contraception during the trial period.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of participants experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs) | Day 1 to day 18 |
| Number of participants with clinically significant laboratory assessment abnormalities | Day 1 to day 18 |
| Number of participants with clinically significant Vital sign abnormalities | Day 1 to day 18 |
| Number of participants with clinically significant 12-lead electrocardiograms (ECGs) abnormalities | Day 1 to day 18 |
| Number of participants with clinically significant physical examination abnormalities | Day 1 to day 18 |
Countries
China
Contacts
CONTACTTranslational Clinical Group officer
Outcome results
None listed